As mentioned in a previous editorial in K2Nytt, the new organizational chart on K2 has been approved by the Institute Council. A new extended management team is part of the reorganization. The extended management team consists of 7 research group leaders and a representative from Stavanger, in addition to the department management. The 7 research group leaders have now been chosen: Emmet
Mc Cormack, Hematology; Eva Gerdts, Cardio; Henning Lygre, Pharmacology / Pharmacy; Per Eystein Lønning, Oncology; Pål Njølstad, Pediatrics; Vidar Steen, Genetics and Harald Wiker, Infection / Microbiology. In the choice of research group leaders to the extended management team, we have tried to let as many subjects as possible be represented. In addition, we have avoided subjects which are already represented in the management group (lung, endo, immunology, gyn / obs). I want to emphasize that there is no disallowance of those not selected. Each of the seven research group leaders will be in the extended management team for 2 years. The team meets once a month. In the extended management team the institute management wants to discuss ongoing matters. Examples are strategy, budget and finances, equipment priorities, educational issues, positions, lab areas and organization of application processes. The 7 research group leaders do not represent anyone but themselves. All the department’s 21 research group leaders will, like earlier, have a direct line to the department management and they will receive the minutes of meetings. The first meeting of the management team was held on Tuesday this week

Per

A core facility is a collection of scientific equipment and highly qualified technical staff made widely available to the research community. The three current core facilities at the Department of Clinical Science: Flow Cytometry Core Facility, Genomics Core Facility and Metabolomics Core Facility, cover important common functions by MOF and UiB as well as regionally and nationally. They are available to all academic users on the same favorable terms and for commercial users of the University’s conditions for contract research.

The department administers the Faculty’s policy regarding sharing of costs and co-authorship when faculty core facilities are used. This policy means that all higher education researchers in Norway, health trusts included, gain access on equal terms, including the same price. More on this see: http://www.uib.no/mofa/67221/kostnadsdeling-og-medforfatterskap (in Norwegian).

The economy of all core facilities will be partially secured through user fees, and through operating models which address the need for reinvestment and equipment renewal.

To ensure that the core facilities are able to provide the best possible service to the communities it is a goal that they are tightly integrated with scientists who are leaders in their fields. Use of core facilities should thus be a more attractive option than buying your own equipment and pay own technical staff, both cost-wise and methodical. Experience has shown that core facilities are the best way to give researchers in Norway access to an updated and maintained instrument park, and to the methodological knowledge they do not have themselves and equipment and staff they could not afford.

The way the core facilities at MOF are operated is based on experiences from the NRC FUGE initiative. The core facilities are operated and financed by the Department / MOF in cooperation with the University of Bergen, Helse Bergen, Helse Vest, the Faculty of Science, Bergen Research Foundation, NRC, and individual groups of researchers.

Important to remember – If the use of a core facility forms part of the basis for a scientific publication the core facility should be mentioned in the acknowledgment section of the publication, for example: “Parts of the work was carried out at the NAME OF CORE FACILITY and was thus supported by the Faculty of Medicine and Dentistry at the University of Bergen and its partners “.

Two great new additions to be especially mentioned are: CyTOF – Mass cytometry with single-cell proteomic opportunities – for Flow (equipment has been delivered and is being tested), and NRC infrastructure funds for equipment for complete human genome sequencing to Genomics.

Roland

The new curriculum in medicine has already been introduced. The first class started this fall, before most clinical departments were ready to wind up their summer vacation.
K2 is primarily responsible for three semesters;
5th semester with pathology, pharmacology, medical biochemistry, preclinical course and circulation / respiration (“Medicine”)
9th semester with gynecology / obstetrics, pediatrics and genetics
12th semester with integrated clinical training and ending with a practical exam

New in this curriculum is that in addition to the medical sciences, “academic pillar” is also emphasized and placed as independent entities on the curriculum. What does that mean?
The objectives can be summarized as providing the student with knowledge of medical science and research, research and ethics, skills in evaluating medical literature, dissemination of scientific results and how to perform statistical analysis. In other words: topics the scientists at K2 know a lot about and that it is nice to communicate and pass on to the younger generation! Teaching in academic subjects is scattered throughout many semesters and “belong” not only to the institute which is responsible for just that specific semester.

I do not know who holds specific expertise in the various academic subjects or how you personally want to contribute, but I hope to find good teachers to the various topics when we get them elaborated from the study planning committee. We don’t want IGS to have a monopoly on research teaching, do we?

This week the first part of this autumn’s teaching day for K1 / K2 was held, the final part will be on October 14th, welcome!

Jone